{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362262946443935104.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/bjs.5894"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fbjs.5894"}},{"identifier":{"@type":"URI","@value":"http://academic.oup.com/bjs/article-pdf/94/10/1189/36686119/bjs5894.pdf"}}],"dc:title":[{"@value":"Neoadjuvant chemotherapy for operable breast cancer"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>Neoadjuvant chemotherapy for early breast cancer can avoid mastectomy by shrinkage of tumour volume. This review assesses the effectiveness of neoadjuvant chemotherapy on clinical outcome.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>All randomized trials comparing neoadjuvant and adjuvant chemotherapy for early breast cancer were reviewed systematically and meta-analyses were performed.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>Fourteen studies randomizing 5500 women were eligible for analysis. Overall survival was equivalent in both groups. In the neoadjuvant group, the mastectomy rate was lower (relative risk 0·71 (95 per cent confidence interval (c.i.) 0·67 to 0·75)) without hampering local control (hazard ratio 1·12 (95 per cent c.i. 0·92 to 1·37)). Neoadjuvant chemotherapy was associated fewer adverse effects.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion</jats:title>\n                  <jats:p>Neoadjuvant chemotherapy is an established treatment option for early breast cancer.</jats:p>\n               </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382262946443935105","@type":"Researcher","foaf:name":[{"@value":"J S D Mieog"}],"jpcoar:affiliationName":[{"@value":"Department of Surgery, Leiden University Medical Centre, Albinusdreef 2, 2300 RC Leiden, The Netherlands"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946443935232","@type":"Researcher","foaf:name":[{"@value":"J A van der Hage"}],"jpcoar:affiliationName":[{"@value":"Department of Surgery, Leiden University Medical Centre, Albinusdreef 2, 2300 RC Leiden, The Netherlands"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262946443935104","@type":"Researcher","foaf:name":[{"@value":"C J H van de Velde"}],"jpcoar:affiliationName":[{"@value":"Department of Surgery, Leiden University Medical Centre, Albinusdreef 2, 2300 RC Leiden, The Netherlands"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00071323"},{"@type":"EISSN","@value":"13652168"}],"prism:publicationName":[{"@value":"British Journal of Surgery"}],"dc:publisher":[{"@value":"Oxford University Press (OUP)"}],"prism:publicationDate":"2007-08-13","prism:volume":"94","prism:number":"10","prism:startingPage":"1189","prism:endingPage":"1200"},"reviewed":"false","dc:rights":["https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fbjs.5894"},{"@id":"http://academic.oup.com/bjs/article-pdf/94/10/1189/36686119/bjs5894.pdf"}],"createdAt":"2007-08-13","modifiedAt":"2021-07-09","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004239694563968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/bjs.5894"},{"@type":"CROSSREF","@value":"10.3892/or.2016.4635_references_DOI_It4kkR39rsmohnOGijG5Jh5lbvQ"}]}